Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) Enterprise Value (2024 - 2025)

Xilio Therapeutics' Enterprise Value history spans 2 years, with the latest figure at -$103.8 million for Q3 2025.

  • For Q3 2025, Enterprise Value fell 69.39% year-over-year to -$103.8 million; the TTM value through Sep 2025 reached -$103.8 million, down 69.39%, while the annual FY2024 figure was -$55.3 million, N/A changed from the prior year.
  • Enterprise Value for Q3 2025 was -$103.8 million at Xilio Therapeutics, up from -$121.6 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$34.0 million in Q1 2024 and bottomed at -$121.6 million in Q2 2025.